MAPT and Alzheimer disease: An IL-1R blocking antibody (anti-IL-1R) significantly alleviates cognitive deficits, markedly attenuates tau pathology, and inhibits amyloid-β formation by decreasing NF-κB transcriptional activity in AD model (Kitazawa et al., 2011).